MiP Pharma has successfully sold its Homburg/Saar production site to Famar Group, a global pharmaceutical CDMO, as part of a strategic focus shift to enhance operational efficiency.

Information on the Target

MiP Pharma, a notable portfolio company operated by capiton, has effectively sold its production facility located in Homburg/Saar to the Famar Group. Famar Group, a globally recognized Contract Development and Manufacturing Organization (CDMO), plans to integrate this facility into its expansive production network and is set to enhance its operations further. This strategic divestiture represents a pivotal move for MiP Pharma as it shifts focus towards its core competencies.

Established with a strong foothold in the pharmaceutical sector, MiP Pharma specializes in manufacturing and distributing generic pharmaceuticals, particularly anti-infectives, through its two state-of-the-art production sites in Germany. With a product range that includes around 400 approved pharmaceutical products, the company has been generating significant revenues in the European market.

Industry Overview in Germany

The pharmaceutical industry in Germany stands as one of the largest in Europe, characterized by its comprehensive regulatory framework and robust infrastructure. As of 2021, the sector contributed around €50 billion to the national economy, with ex